Metropolitan Life Insurance Co. NY maintained its position in shares of GenMark Diagnostics, Inc. (NASDAQ:GNMK) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 29,013 shares of the medical equipment provider’s stock at the end of the first quarter. Metropolitan Life Insurance Co. NY’s holdings in GenMark Diagnostics were worth $372,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently modified their holdings of GNMK. FMR LLC boosted its position in shares of GenMark Diagnostics by 1.4% in the first quarter. FMR LLC now owns 7,057,680 shares of the medical equipment provider’s stock valued at $90,480,000 after buying an additional 97,034 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of GenMark Diagnostics by 5.1% in the first quarter. JPMorgan Chase & Co. now owns 3,538,138 shares of the medical equipment provider’s stock valued at $45,359,000 after buying an additional 170,977 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of GenMark Diagnostics by 3.1% in the first quarter. Vanguard Group Inc. now owns 1,956,681 shares of the medical equipment provider’s stock valued at $25,084,000 after buying an additional 58,691 shares in the last quarter. Northpointe Capital LLC boosted its position in shares of GenMark Diagnostics by 25.4% in the first quarter. Northpointe Capital LLC now owns 1,077,196 shares of the medical equipment provider’s stock valued at $13,810,000 after buying an additional 217,847 shares in the last quarter. Finally, Citadel Advisors LLC boosted its position in shares of GenMark Diagnostics by 105.7% in the first quarter. Citadel Advisors LLC now owns 783,765 shares of the medical equipment provider’s stock valued at $10,048,000 after buying an additional 402,832 shares in the last quarter. 93.07% of the stock is owned by institutional investors.

GenMark Diagnostics, Inc. (NASDAQ:GNMK) traded down 0.93% during trading on Friday, reaching $9.60. 317,784 shares of the company’s stock were exchanged. The company’s market cap is $524.80 million. GenMark Diagnostics, Inc. has a 12-month low of $8.03 and a 12-month high of $13.67. The stock’s 50-day moving average is $11.19 and its 200-day moving average is $12.12.

GenMark Diagnostics (NASDAQ:GNMK) last posted its earnings results on Tuesday, August 1st. The medical equipment provider reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by $0.05. GenMark Diagnostics had a negative net margin of 111.96% and a negative return on equity of 109.89%. The business had revenue of $12.36 million during the quarter, compared to analysts’ expectations of $12.44 million. During the same period last year, the business posted ($0.30) earnings per share. The company’s revenue for the quarter was down 1.2% compared to the same quarter last year. Analysts predict that GenMark Diagnostics, Inc. will post ($1.07) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Metropolitan Life Insurance Co. NY Maintains Stake in GenMark Diagnostics, Inc. (GNMK)” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://www.dailypolitical.com/2017/08/19/metropolitan-life-insurance-co-ny-maintains-stake-in-genmark-diagnostics-inc-gnmk.html.

GNMK has been the subject of several recent analyst reports. BidaskClub cut shares of GenMark Diagnostics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. Canaccord Genuity reaffirmed a “buy” rating and set a $14.00 price objective (down previously from $17.00) on shares of GenMark Diagnostics in a research note on Monday, August 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 price objective (up previously from $15.00) on shares of GenMark Diagnostics in a research note on Wednesday, May 3rd. BTIG Research reaffirmed a “buy” rating and set a $17.00 price objective on shares of GenMark Diagnostics in a research note on Wednesday, May 17th. Finally, Zacks Investment Research cut shares of GenMark Diagnostics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 3rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $15.80.

About GenMark Diagnostics

GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

Want to see what other hedge funds are holding GNMK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GenMark Diagnostics, Inc. (NASDAQ:GNMK).

Institutional Ownership by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.